CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Questionnairesbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03659214
NCT03659214N/ACompleted
CompareCT.gov

Impact of the Introduction of ORKAMBI on Anxiety, Depression, Quality of Life and Adherence of Adolescents and Young Adults

Assistance Publique - Hôpitaux de Paris·observational·Posted Sep 6, 2018·Updated Nov 20, 2025

In Brief

An observational study evaluating Questionnaires for Cystic Fibrosis. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The aim of this project is to evaluate the psychological reshuffle induced by ORKAMBI. The particular focus of this study is the consequence of its introduction on anxiety, depression, quality of life and adherence to all cystic fibrosis (CF) treatment. To answer this question investigators will monitor the psychological function of CF adolescents and young adults treated with ORKAMBI and compare them to CF adolescents and young adults not treated with ORKAMBI.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesFrance
CollaboratorsVERTEX Pharmaceutical, URC-CIC Paris Descartes Necker Cochin

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 6, 2018
Enrollment StartDec 1, 2017
Primary CompletionJan 19, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.8 years ago

Interventions

Questionnairesbehavioral

Answering 4 questionnaires : anxiety, depression, quality of life and adherence